Enzalutamide (Enz) is an anti-androgen used for treatment of metastatic, advanced prostate cancer. Unfortunately, this treatment will eventually lead to resistance. Understanding the mechanisms behind Enz-resistance will provide useful in predicting Enz-response in patients as well as in defining new therapeutic targets. We generated an in vitro model for Enz-resistance by long-term treatment of LNCaP cells. The resulting cell line was named LNCaP-R. The LNCaP-R cells were investigated for transcriptomic changes via RNAseq analysis. For a large set of androgen-regulated genes in LNCaP and especially for the PSA gene, we observed an attenuated androgen response in the LNCaP-R. This lower AR activity could not be attributed to lower levels of...
PhD ThesisProstate cancer is usually androgen-dependent and consequently, initial therapy for many p...
The effect of androgens is mediated by the androgen receptor (AR), a ligand-inducible transcription ...
In prostate cancer, aberrant androgen receptor (AR) function leads to the deregulation of AR targe...
INTRODUCTION Enzalutamide (Enz) is a recently FDA-approved anti-androgen used for treatment of meta...
Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) a...
Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) a...
Potent androgen receptor pathway inhibitors such as Enzalutamide (ENZ) and Abiraterone (Abi) have be...
Representative in vitro model systems that accurately model response to therapy and allow the identi...
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with c...
Development of castration-resistant prostate cancer (CRPC) is thought to be dependent on androgen re...
An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year ...
While effective, resistance to 1st generation and 2nd generation androgen receptor (AR) pathway inhi...
Prostate cancer is the most commonly diagnosed cancer in men and nearly 30,000 patients will die thi...
Inhibition of the androgen receptor (AR) by second-generation anti-androgens is a standard treatment...
<p><b>Background:</b> Enzalutamide, a novel androgen receptor (AR) signaling inhibitor, has been wid...
PhD ThesisProstate cancer is usually androgen-dependent and consequently, initial therapy for many p...
The effect of androgens is mediated by the androgen receptor (AR), a ligand-inducible transcription ...
In prostate cancer, aberrant androgen receptor (AR) function leads to the deregulation of AR targe...
INTRODUCTION Enzalutamide (Enz) is a recently FDA-approved anti-androgen used for treatment of meta...
Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) a...
Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) a...
Potent androgen receptor pathway inhibitors such as Enzalutamide (ENZ) and Abiraterone (Abi) have be...
Representative in vitro model systems that accurately model response to therapy and allow the identi...
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for men with c...
Development of castration-resistant prostate cancer (CRPC) is thought to be dependent on androgen re...
An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year ...
While effective, resistance to 1st generation and 2nd generation androgen receptor (AR) pathway inhi...
Prostate cancer is the most commonly diagnosed cancer in men and nearly 30,000 patients will die thi...
Inhibition of the androgen receptor (AR) by second-generation anti-androgens is a standard treatment...
<p><b>Background:</b> Enzalutamide, a novel androgen receptor (AR) signaling inhibitor, has been wid...
PhD ThesisProstate cancer is usually androgen-dependent and consequently, initial therapy for many p...
The effect of androgens is mediated by the androgen receptor (AR), a ligand-inducible transcription ...
In prostate cancer, aberrant androgen receptor (AR) function leads to the deregulation of AR targe...